Table 4.

Adverse event profile after administration of multiple doses of LY2886721

Adverse event	Number of adverse events (subjects)
	Placebo (n = 20)		LY2886721 (n = 35)
	Placebo (n = 20)		5 mg (n = 10)		15 mg (n = 10)		35 mg (n = 9)		70 mg (n = 6)		All doses (n = 35)
	Tot	Rel	Tot	Rel	Tot	Rel	Tot	Rel	Tot	Rel	Tot	Rel
Headache	2 (1)	1 (1)	0 (0)	0	0 (0)	0	1 (1)	1 (1)	0 (0)	0	1 (1)	1 (1)
Procedural headache	2 (2)^*	0	0 (0)	0	1 (1)	0	0 (0)	0	1 (1)	0	2 (2)	0
Cough	0 (0)	0	0 (0)	0	0 (0)	0	0 (0)	0	1 (1)	0	1 (1)	0
Dry mouth	1 (1)	0	0 (0)	0	0 (0)	0	0 (0)	0	0 (0)	0	0 (0)	0
Gingivitis	1 (1)	0	0 (0)	0	0 (0)	0	0 (0)	0	0 (0)	0	0 (0)	0
Insomnia	0 (0)	0	0 (0)	0	0 (0)	0	0 (0)	0	1 (1)	0	1 (1)	0
Visual field tests abnormal	1 (1)	0	1 (1)	0	0 (0)	0	0 (0)	0	0 (0)	0	1 (1)	0
Orthostatic hypotension	0 (0)	0	1 (1)	1 (1)	0 (0)	0	0 (0)	0	0 (0)	0	1 (1)	1 (1)
Muscle spasms	0 (0)	0	0 (0)	0	1 (1)	0	0 (0)	0	0 (0)	0	1 (1)	0
Libido decreased	0 (0)	0	0 (0)	0	1 (1)	1 (1)	0 (0)	0	0 (0)	0	1 (1)	1 (1)
Rash	0 (0)	0	0 (0)	0	0 (0)	0	0 (0)	0	1 (1)	0	1 (1)	0
Scotoma	1 (1)	0	0 (0)	0	0 (0)	0	0 (0)	0	0 (0)	0	0 (0)	0
Sinus congestion	0 (0)	0	0 (0)	0	1 (1)	0	0 (0)	0	0 (0)	0	1 (1)	0
Chest pain	0 (0)	0	0 (0)	0	0 (0)	0	1 (1)	0	0 (0)	0	1 (1)	0
Oral herpes	0 (0)	0	0 (0)	0	0 (0)	0	1 (1)	0	0 (0)	0	1 (1)	0
URI	1 (1)	0	0 (0)	0	0 (0)	0	0 (0)	0	0 (0)	0	0 (0)	0
Viral infection	0 (0)	0	0 (0)	0	0 (0)	0	1 (1)	0	0 (0)	0	1 (1)	0

Adverse event, all-cause and related to study drug, by treatment, in order of frequency.
Rel, Related to study drug; Tot, total; URI, upper respiratory tract infection.
↵*Only this adverse event was moderate in severity and all others were mild in severity. None was considered severe.